



NEUROREHABILITATION  
& RESEARCH HOSPITAL

## MEDICATION MANAGEMENT OF BRAIN INJURED PATIENTS

Kathy Collins PharmD, BCPS  
Senior Clinical Pharmacist  
Craig Hospital

# DISCLOSURE


- Dr. Collins has no financial or non-financial conflicts of interest related to this activity.
- Non-FDA approved products and indications will be discussed during this presentation.

# OBJECTIVES

- Describe the obstacles for standardizing medication treatments in brain injured patients.
- Identify at least 3 neurotransmitter targets for pharmacotherapy.
- Discuss factors that should be considered in choosing medication treatment in a brain injured patient.
- List 2 medications that should be used with caution in a brain injured patient.




# Spot 10 differences



# OBSTACLES TO DEVELOPING STANDARD OF CARE

## Differences among patient population

- Individual injury
  - Neuroanatomy
  - Neurophysiology
  - Neurochemistry
- Individual pre-morbid function
- Individual post-injury sequela





# OBSTACLES TO DEVELOPING STANDARD OF CARE


- Variable responses to medications
  - Some patients benefit
  - Some patients get worse
  - Some patients more sensitive
  - Some patients resistant or need extreme doses
- Compliance issues
  - Memory
  - Adverse effects and interactions
- Measuring cognition and behavior
  - Patient may test well, but function poorly
  - Patient may test poorly, but function well
- Variations in biochemistry balance

# OBSTACLES TO DEVELOPING STANDARD OF CARE

Standards	Guidelines	Options
Based on at least 1, well-designed class I study with adequate sample OR overwhelming class II evidence	Based on well-designed class II studies	<b>Based on class II or class III studies with additional grounds to support a recommendation</b>

**\* Lack of evidence ≠ lack of efficacy \***


# NEUROCHEMICAL APPROACH TO TREATMENT





# NEUROCHEMICAL APPROACH TO TREATMENT

## Serotonin



- Memory
- Emotion
- Sleep/wake

### Side effects

- Nausea
- Sexual side effects

Selective serotonin reuptake inhibitors (SSRIs)

Serotonin/norepinephrine reuptake inhibitors (SNRIs)

Tricyclic antidepressants (TCAs)

- Sertraline (Zoloft®)
- Citalopram (Celexa®)

- Duloxetine (Cymbalta®)
- Venlafaxine (Effexor®)

- Amitriptyline (Elavil®)
- Nortriptyline (Pamelor®)

# NEUROCHEMICAL APPROACH TO TREATMENT

## Dopamine



- Voluntary movement
- Motivation/initiation
- Memory

### Side effects

- Nausea
- Headache
- Impulsivity

Parkinson's disease medications  
(↑dopamine)

NMDA antagonists  
(↑dopamine/↓glutamate)

Atypical antipsychotics  
(↑serotonin/dopamine)

- Bromocriptine (Parlodel®)
- Levodopa/carbidopa (Sinemet®)

- Amantadine (Symmetrel®)
- Memantine (Namenda®)

- Risperidone (Risperdal®)
- Aripiprazole (Abilify®)
- Quetiapine (Seroquel®)

# NEUROCHEMICAL APPROACH TO TREATMENT

## Norepinephrine

- Arousal
- Attention
- Improve cognitive function



## Side effects

- Agitation
- Insomnia
- Decrease appetite

Stimulants  
(↑  
norepinephrine/dopamine)

- Methylphenidate (Ritalin®)
- Dextroamphetamine (Dexedrine®)
- Atomoxetine (Strattera®)

β-blockers  
(↓norepinephrine)

- Propranolol (Inderal®)

# NEUROCHEMICAL APPROACH TO TREATMENT

## Acetylcholine

- Memory
- Improve fatigue



## Side effects

- Nausea
- Insomnia
- Impulsivity

Acetylcholinesterase inhibitors (↑ acetylcholine)

- Donepezil (Aricept®)
- Galantamine (Razadyne®)
- Rivastigmine (Exelon®)

# NEUROCHEMICAL APPROACH TO TREATMENT

## Glutamate




- Excitatory transmitter
- Overstimulation → cell death
- Affects cognition

## Side effects

- Headache
- Insomnia

NMDA antagonists  
(↑dopamine/↓glutamate)

- Amantadine (Symmetrel®)
- Memantine (Namenda®)
- Dextromethorphan (Neudexta®)





# APPROACH TO TREATMENT

Control environment

Remove medication contributors

Consider medication treatment

## Medication considerations

- Age
- Comorbidities
- Drug interactions
- Sensitivities
- Adherence
- Costs



# PATIENT CASE

- MF is a 58 year old male who sustained a traumatic brain injury (TBI) due to a un-helmeted motorcycle accident approximately 2 months ago. Toxicology screen was positive for alcohol, marijuana, and cocaine.
- Past medical history is significant for asthma, hypertension, 20 pack year smoker.
- His course has been complicated by bilateral deep vein thrombosis (DVTs), occurrence of seizure, urinary retention, need for enteral feeding, and significant shoulder pain.



# PATIENT CASE

## Today's presentation

- Patient is agitated, un-oriented with reports of striking nursing staff and verbal outbursts that are un-intelligible.
- His blood pressures are labile.
- He is holding his head and moaning.
- Nursing reports poor sleep.

# MEDICATION TREATMENT TARGETS

Post Traumatic Headache  
Hyper arousal/ aggression  
Sleep  
Cognition/Memory  
Aphasia



# POST TRAUMATIC HEADACHE

- Occurring in 25-78 % of individuals with mild TBI
- More frequent in individuals with mild versus moderate or severe TBI
- Exacerbated by very mild physical or mental exertion
- Can be episodic or continuous

## Presentation Types

- Migraine headache
- Tension headache
- Medication overuse headache

# POST TRAUMATIC HEADACHE

## ABORTIVE TREATMENT OPTIONS

Acetaminophen ± combinations	<ul style="list-style-type: none"><li>• APAP/caffeine/ibuprofen</li></ul>
Anti-emetics	<ul style="list-style-type: none"><li>• Prochlorperazine</li><li>• Promethazine</li></ul>
NSAIDS	<ul style="list-style-type: none"><li>• Ibuprofen</li><li>• Ketorolac</li></ul>
Serotonin receptor agonists	<ul style="list-style-type: none"><li>• Sumatriptan</li><li>• Rizatriptan</li></ul>
Calcitonin gene-related protein (CGRP) inhibitors	<ul style="list-style-type: none"><li>• Ubrogepant</li><li>• Rimegepant</li></ul>

### Patient considerations

- Consider scheduled dosing
- Caution for medication overuse
- Avoid sedating or activating agents
- Assess bleeding risk





# POST TRAUMATIC HEADACHE

## PROPHYLAXIS OPTIONS

B-blockers

TCAs

Anti-seizure  
meds

SSRIs

Supplements  
(Mg, B5,  
melatonin)

Initiate headache prophylaxis if:

- migraine occurs >1 /week or if tension headache occurs >3/week
- is disabling despite aggressive interventions
- affecting ADLs

# HYPER-AROUSAL

## Agitation/Aggression

- Common during post-traumatic amnesia
- Affects safety and adherence to treatment
- Most common in the acute phase, but can persist long term

## Storming - dysautonomia

- Tachycardia
- Dystonia
- Diaphoresis
- Hypertension



# HYPER-AROUSAL

Atypical  
antipsychotics

- Aripiprazole
- Risperidone
- Quetiapine

SSRIs (↓)


- Citalopram
- Sertraline

NMDA antagonists  
(↑dopamine/↓glutamate)

- Amantadine
- Memantine

β-blockers  
(↓ norepinephrine)

- Propranolol



## Patient Considerations

- Prioritize safety
- Consider PMH of HTN
- Monitor closely for side effects



# SLEEP

Sleep disorders include

- Hyper somnolence
- Sleep related breathing disorders

## Prevalent and persistent

- Present in 30-70% of patients with a history of brain injury
- Higher in the acute phase
- Usually decreases after a few years



# SLEEP

Trazodone

Melatonin


Orexin  
inhibitors

SSRIs

“Z” meds  
(zolpidem)



Serotonin



Others:  
histamine  
orexin  
melatonin

## Patient Considerations

- Urinary retention
- Seizure history
- Goal is short term treatment



# COGNITION/MEMORY


- 40-60% of patients 1-3 months following TBI
- Correlates with injury severity
- Prolonged
- Removing or decreasing medications may be considered a “therapeutic event”





# COGNITION/MEMORY

Stimulants (↑ norepinephrine)	<ul style="list-style-type: none"><li>• Methylphenidate</li><li>• Dextroamphetamine</li><li>• Atomoxetine</li></ul>
NMDA antagonists (↑dopamine/↓glutamate)	<ul style="list-style-type: none"><li>• Amantadine</li><li>• Memantine</li></ul>
Acetylcholinesterase inhibitors	<ul style="list-style-type: none"><li>• Donepezil</li></ul>



## Patient Considerations


- Avoid stimulants
- Monitor for side effects
- Set expectations for benefit



# APHASIA

“Drug therapy might improve recovery from loss of language (aphasia) after stroke, **but no drug has yet been proven to do more good than harm.**”

J Greener, Cochrane Stroke Group,  
Division of Clinical Neurosciences. 2010



# APHASIA

TCAs

SSRIs

NMDA antagonists


Stimulants

Dopamine agonists

Acetylcholinesterase  
inhibitors

## Patient considerations

- Consider medication if useful for other comorbidities



# MEDICATIONS TO USE WITH CAUTION


## Benzodiazepines

- Common for insomnia and agitation
- Exacerbate confusion (“benzodiazepine psychosis”)
- Impair memory
- Abuse potential
- Stopping the medication may be the “therapeutic event”

## Typical antipsychotics (1<sup>st</sup> generation)

- Block dopamine
- May interfere with cognitive recovery
- Sedation->confusion-> aggression

# PATIENT CASE



## Treatment plan

- Initiate one intervention at a time
- Start low, go slow
- Monitor for response and side effects
- Trial lower doses with improvement or when stable
- Re-evaluate often





THANK YOU!



**CRAIG**

NEUROREHABILITATION  
& RESEARCH HOSPITAL